- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07278479
Étude du [212Pb]Pb-DOTAM-MAM279 chez des patients atteints de cancer du poumon à petites cellules et d'autres tumeurs solides exprimant DLL3
Étude de phase 1/2a évaluant la sécurité, la tolérabilité et l'efficacité du [212Pb]Pb-DOTAM-MAM279 chez des patients atteints de cancer du poumon à petites cellules et d'autres tumeurs solides exprimant DLL3
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [212Pb]Pb-MP0712, in patients aged ≥18 years with Small Cell Lung Cancer and other locally advanced or metastatic DLL3 positive tumors.
Aperçu de l'étude
Statut
Les conditions
- Carcinome neuroendocrinien à grandes cellules
- Cancer du poumon à petites cellules (SCLC)
- Carcinome neuroendocrinien extrapulmonaire (EP-NEC)
- Carcinome neuroendocrinien pulmonaire à grandes cellules du poumon (LCNEC)
- Tumeur neuroendocrine gastro-entéro-pancréatique (TNE GEP)
- NEC de la vessie
- Autres epNEC exprimant DLL3
Intervention / Traitement
Description détaillée
This is a phase I/IIa, open-label, multi-center study to evaluate the safety, tolerability, dosimetry, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of [212Pb]Pb-MP0712 in patients with SCLC and other advanced DLL3-expressing solid tumors. The study consists of a dose escalation part, followed by a dose expansion part. Once the recommended radioactive dose(s) [212Pb]Pb-MP0712 for further clinical evaluation are determined, the dose expansion part will further characterize the safety, tolerability, and preliminary anti-tumor activity of [212Pb]Pb-MP0712. The study will enable evaluation of the safety, dosimetry, PK, and imaging properties of [203Pb]Pb-MP0712.
Type d'étude
Inscription (Estimé)
Phase
- Phase 2
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Medical Director MPAG
- Numéro de téléphone: +41 44 755 77 00
- E-mail: info@molecularpartners.com
Lieux d'étude
-
-
Florida
-
Tampa, Florida, États-Unis, 33612
- Recrutement
- Moffitt Cancer Center
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30322
- Recrutement
- Emory University Hospital
-
Contact:
- Ryan Hanula
- Numéro de téléphone: 404-778-5141
- E-mail: rhanula@emory.edu
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Recrutement
- University of Chicago
-
-
Maryland
-
Glen Burnie, Maryland, États-Unis, 21061
- Recrutement
- United Theranostics
-
Contact:
- Amanda Huggins
- Numéro de téléphone: 667-HOPENOW
- E-mail: clinicaltrial@unithera.com
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68130
- Recrutement
- Nebraska Cancer Specialists
-
Contact:
- Research Director
- Numéro de téléphone: 402-955-2691
- E-mail: clinicaltrials@nebraskacancer.com
-
-
New Jersey
-
Princeton, New Jersey, États-Unis, 08540
- Recrutement
- United Theranostics
-
Contact:
- Amanda Huggins
- Numéro de téléphone: 667-HOPENOW
- E-mail: clinicaltrial@unithera.com
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44106
- Recrutement
- University Hospitals Cleveland Medical Center
-
Contact:
- Dr A.Dowlati
- Numéro de téléphone: 216-368-1122
- E-mail: afshin.dowlati@uhhospitals.org
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Recrutement
- The University of Texas MD Anderson Cancer Center
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Key Inclusion Criteria:
-
Age ≥ 18 years old
-
Histologically or cytologically confirmed: I. advanced extensive or limited SCLC or LC NECs of the lung
- SCLC (extensive stage, or limited stage) patients with progression or recurrence following at least two prior line of systemic platinum based therapy and immunotherapy or are not suitable or tolerating the standard of care treatment as second line of systemic therapy, or
- LC NEC of the lung patients with progression or recurrence following at least one prior line of systemic therapy, or II. epNECs with progression or recurrence following at least one prior line of systemic therapy:
- Gastroenteropancreatic NECs (GEPNEC), or
- Cervical NECs, or
- Bladder NECs, or
- other epNECs with previously confirmed DLL3 expression by IHC.
- Patients with prior DLL3-targeted therapy are allowed.
-
For epNECs in Part 1 and Part 2 and SCLC or LC NECs of the lung in Part 2: DLL3-positivity by [203Pb]Pb-DOTAM-MAM279 SPECT/CT
-
Radiographically documented disease progression or recurrence during or after the last line of systemic treatment therapy
-
At least one measurable disease per RECIST v1.1.
-
Adequate bone marrow reserve and organ function as demonstrated by complete blood count, and biochemistry in blood and urine at Screening
-
Adequate blood counts: Hemoglobin ≥9 g/dL; Absolute neutrophil count (ANC) ≥1.5 × 10^9/L; Platelets ≥100 × 10^9/L; White blood cells (WBC) ≥2.5 x 10^9/L;
-
Adequate hepatic function
-
Adequate renal function: Calculated glomerular filtration rate (GFR) >60mL/min (using Cockroft-Gault formula).
-
Patients with known central nervous system (CNS) metastasis will be eligible if they are clinically stable.
Key Exclusion Criteria:
- Uncontrolled intercurrent illness
- Patients who have not had resolution of all clinically significant toxic effects of prior systemic cancer therapy, surgery, or radiotherapy to Grade ≤1 (except for grade ≤2 alopecia, or stable grade 2 sensory neuropathy, according to the last CTCAE version).
- Active clinically significant cardiac disease
- Evidence of interstitial lung disease or active, non-infectious pneumonitis.
- History of other malignancy within the past 2 years with exceptions.
Other protocol-defined inclusion/exclusion criteria may apply.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: [203Pb]Pb-DOTAM-MAM279/[212Pb]Pb-DOTAM-MAM279
Patients will receive [203Pb]Pb-DOTAM-MAM279 for Imaging/Dosimetry followed by [212Pb]Pb-DOTAM-MAM279 for treatment |
Radioligand Therapy
Autres noms:
Radioligand Imaging Agent
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To assess incidence and severity of safety events following administration of [212Pb]Pb-DOTAM-MAM279
Délai: until 5 years after last dose
|
Type, frequency and severity of adverse events (AEs), and serious adverse events (SAEs), Adverse events of special interest (AESI) and Dose Limiting Toxicities (DLT) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) |
until 5 years after last dose
|
|
To assess dose modifications of [212Pb]Pb-DOTAM-MAM279
Délai: until 5 years after last dose
|
Frequency and duration of dose changes |
until 5 years after last dose
|
|
To estimate the maximum tolerated dose (MTD) and/or to define the recommended phase 2 dose (RP2D) for SCLC/LCNEC of the lung and epNECs
Délai: Phase 1, from start of treatment to end of first cycle (day 1 - 28)
|
Incidence of dose limiting toxicities |
Phase 1, from start of treatment to end of first cycle (day 1 - 28)
|
|
To evaluate the preliminary anti-tumor activity of [212Pb]Pb-DOTAM-MAM279 in the dose expansion part
Délai: Phase 2a only; 12 months
|
Objective Response Rate (ORR) in the expansion phase ORR is defined as the percentage of patients with partial response (PR) or complete response (CR) as per RECIST v1.1 |
Phase 2a only; 12 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
To assess maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Délai: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine maximum concentration (Cmax) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the area under the curve (AUC) from time 0 to the time of the last quantifiable concentration of [203Pb]Pb-DOTAM-MAM279
Délai: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine AUC of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Délai: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine half-live(s) (t½) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Délai: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine clearance (CL) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To assess the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279
Délai: up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
Blood and serum samples will be drawn to determine the volume of distribution (Vd) of [203Pb]Pb-DOTAM-MAM279 / [212Pb]Pb-DOTAM-MAM279 |
up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration; up to 14 days following [212Pb]Pb-DOTAM-MAM279 administration]
|
|
To quantitatively predict radiation absorbed doses for therapeutic [212Pb]Pb-DOTAM-MAM279 from [203Pb]Pb-DOTAM-MAM279
Délai: Phase 1; up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration
|
Estimation of [212Pb]Pb-DOTAM-MAM279 absorbed dose for healthy organs and tumor lesions based on dosimetry analysis of [203Pb]Pb-DOTAM-MAM279 |
Phase 1; up to 7 days following [203Pb]Pb-DOTAM-MAM279 administration
|
|
To assess incidence and severity of safety events following administration of [203Pb]Pb-DOTAM-MAM279
Délai: up to 10 days following [203Pb]Pb-DOTAM-MAM279 administration
|
Type, frequency and severity of adverse events (AEs) and serious adverse events (SAEs) using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v5.0 |
up to 10 days following [203Pb]Pb-DOTAM-MAM279 administration
|
|
To evaluate PFS
Délai: Phase 2a only; 12 months
|
Progression-Free Survival (PFS) determined as the time from C1D1 to the date of progression, defined as the first documented progression as per RECIST v1.1 or death for any cause |
Phase 2a only; 12 months
|
|
To evaluate DoR
Délai: Phase 2a only; 12 months
|
Duration of response (DoR) in patients with a CR or PR from date of first date of response to the date of RECIST 1.1 progression or death |
Phase 2a only; 12 months
|
|
To evaluate DCR
Délai: Phase 2a only; 12 months
|
Disease control rate (DCR) defined as the percentage of patients who have achieved CR, PR, or stable disease (SD) |
Phase 2a only; 12 months
|
|
To evaluate OS
Délai: Phase 2a only; approx. 5 years
|
Overall survival (OS) defined as the time from C1D1 to death from any cause |
Phase 2a only; approx. 5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies des voies respiratoires
- Tumeurs par type histologique
- Maladies pulmonaires
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Tumeurs des voies respiratoires
- Tumeurs thoraciques
- Tumeurs pulmonaires
- Carcinome
- Tumeurs neuroectodermiques
- Tumeurs, cellules germinales et embryonnaires
- Tumeurs, tissu nerveux
- Carcinome bronchique
- Tumeurs bronchiques
- Tumeurs neuroendocrines
- Carcinome pulmonaire à petites cellules
- Carcinome neuroendocrinien
Autres numéros d'identification d'étude
- MP0712-CP101
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .